The effectiveness and underlying mechanisms of organoid transplantation therapy in liver ischemia-reperfusion injury (IRI) remain underexplored. We aimed to investigate the therapeutic potential and biological processes of human adult stem cells (hASCs)-derived hepatic organoids (hHOs) in treating liver IRI in an immune-deficient murine model.